← Back to Search

Iron Chelator

Deferasirox plus amlodipine for Iron Overload (CANALI Trial)

N/A
Waitlist Available
Led By Kevin HM Kuo, MD MSc FRCPC
Research Sponsored by Kevin H.M. Kuo, MD, MSc, FRCPC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months following randomization
Awards & highlights

CANALI Trial Summary

This is a randomized, open label, two arms superiority trial of a representative population of patients with a primary diagnosis of transfusion dependent thalassemia with evidence of moderate cardiac iron overload, defined as an average T2* MRI parameter at the mid inter-ventricular septum between 10 and 20ms.

Eligible Conditions
  • Iron Overload
  • Beta Thalassemia

CANALI Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months following randomization
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months following randomization for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in cardiac T2*
Secondary outcome measures
Change in left ventricular ejection fraction
Number of Participants with Adverse Events

CANALI Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Deferasirox plus amlodipineExperimental Treatment2 Interventions
deferasirox iron chelation therapy with amlodipine
Group II: DeferasiroxActive Control1 Intervention
deferasirox iron chelation therapy and standard of care by the treating physician
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Amlodipine
FDA approved
Deferasirox
FDA approved

Find a Location

Who is running the clinical trial?

Kevin H.M. Kuo, MD, MSc, FRCPCLead Sponsor
1 Previous Clinical Trials
50 Total Patients Enrolled
Kevin HM Kuo, MD MSc FRCPCPrincipal InvestigatorUniversity Health Network, Toronto

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients
Kevin H.M. Kuo, MD, MSc, FRCPC 2015. "Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02474420.
All > Thalassemia
~6 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top